1 week Ago By ABMN Staff
Shares of Autolus Therapeutics plc ( NASDAQ:AUTL – Get Free Report ) fell 3.4% during mid-day trading on Friday . The stock traded as low as $4.
29 and last traded at $4.29. 95,826 shares traded hands during trading, a decline of 93% from the average session volume of 1,440,018 shares.
The stock had previously closed at $4.44. Analyst Ratings Changes Several equities analysts have recently commented on AUTL shares.
Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd.
One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.
70. Get Our Latest Report on AUTL Autolus Therapeutics Stock Performance Autolus Therapeutics ( NASDAQ:AUTL – Get Free Report ) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.
22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03).
Analysts forecast that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year. Institutional Inflows and Outflows Hedge funds have recently modified their holdings of the stock.
ProShare Advisors LLC acquired a new stake in Autolus Therapeutics during the second quarter worth about $43,000. Daiwa Securities Group Inc. boosted its position in shares of Autolus Therapeutics by 2,659.
7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after acquiring an additional 15,293 shares in the last quarter.
Bayesian Capital Management LP bought a new position in Autolus Therapeutics in the first quarter valued at approximately $100,000. B. Riley Wealth Advisors Inc.
acquired a new position in Autolus Therapeutics during the first quarter valued at approximately $108,000. Finally, SG Americas Securities LLC bought a new stake in Autolus Therapeutics during the first quarter worth $127,000. Institutional investors own 72.
83% of the company’s stock. About Autolus Therapeutics ( Get Free Report ) Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
See Also Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
